Advertisement
U.S. markets open in 4 hours 28 minutes
  • S&P Futures

    5,306.00
    -2.25 (-0.04%)
     
  • Dow Futures

    40,153.00
    +9.00 (+0.02%)
     
  • Nasdaq Futures

    18,491.00
    -12.75 (-0.07%)
     
  • Russell 2000 Futures

    2,135.10
    -3.30 (-0.15%)
     
  • Crude Oil

    81.74
    +0.39 (+0.48%)
     
  • Gold

    2,216.50
    +3.80 (+0.17%)
     
  • Silver

    24.56
    -0.19 (-0.78%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.95
    +0.17 (+1.33%)
     
  • dólar/libra

    1.2607
    -0.0031 (-0.25%)
     
  • USD/JPY

    151.4450
    +0.1990 (+0.13%)
     
  • Bitcoin USD

    70,577.88
    +975.09 (+1.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.14
    +22.16 (+0.28%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Medicines Co. completes purchase of ProFibrix

Medicines Co. closes purchase of ProFibrix after successful study of surgical bleeding drug

PASIPPANY, N.J. (AP) -- Medicines Co. said Monday that it has completed its purchase of ProFibrix BV after a bleeding-control drug that ProFibrix is developing met its goals in a late-stage clinical trial.

The stock jumped $2.02, or over 6 percent, to $33.49 in aftermarket trading. Shares of Medicines Co. rose 10 cents to $31.47 on Monday before the positive trial results were reported.

Medicines Co. agreed to buy ProFibrix in June in a deal that was contingent on a successful trial of Fibrocaps. Fibrocaps mixes two blood clotting proteins called fibrinogen and thrombin to form a dry topical powder that is designed to help control bleeding during surgery. Medicines Co. said sales of the product could reach about $300 million a year if it is approved in most major markets.

ProFibrix also has developed a dry powder spray to help surgeons apply Fibrocaps.

Medicines Co. made a $10 million upfront payment in June and paid $90 million at closing. It could pay another $140 million based on regulatory development and sales milestones. The company said it expects to report $9 million to $12 million in one-time costs related to the deal during the third quarter.

Medicines Co.'s main product is the anti-clotting drug Angiomax. In the first half of 2013 sales of Angiomax rose 13 percent to $294.1 million.

Advertisement